Stephen Magie, MD
Retina Specialist · Conway, ARNPI 1306820360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novartis at 31.7% of the total. Reporting peaked in 2019 at $169 and has fallen 59.5% since, to $69 in 2024.
Across 29 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$200
- Genentech USA, Inc.$125
- Alimera Sciences, Inc.$76
- Regeneron Healthcare Solutions, Inc.$52
- AbbVie$34
- AstraZeneca$22
- plus $122 from 7 others
What the payments were for
- Food & beverage$632100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $200 |
| Genentech USA, Inc. | 6 | $125 |
| Alimera Sciences, Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| AbbVie | 2 | $34 |
| AstraZeneca | 1 | $22 |
| Amgen | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
How this compares
Too few retina specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 20 | $1,004 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $758 |
| Latanoprost | 35 | $571 |
| Ketorolac Tromethamine | 12 | $189 |
| Timolol Maleate | 18 | $156 |
| Brimonidine Tartrate | 14 | $88 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Conway
- Alice KennedyConway$5K
- Serrhel AdamsSpringdale$48K
- John DellacroceFayetteville$14K
- Cedric PrattLittle Rock$11K
- Bradley HughesLittle Rock$4K
- Stephen DavisLittle Rock$3K
- John KingLittle Rock$3K
- Gerald WareLittle Rock$3K
- Muhammad ShamimLittle Rock$2K
- Paul HrubyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.